Introduction
============

The ongoing burden of type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) -- in terms of cost, morbidity, and mortality[@b1-dmso-10-065],[@b2-dmso-10-065] -- underscores a need for under-standing the underlying pathogenesis and for motivating patients toward prevention.[@b3-dmso-10-065],[@b4-dmso-10-065] Although the pathophysiology for both diseases is complex, T2DM and CVD share underlying processes related to systemic inflammation, oxidative stress, and adipocyte dysfunction.[@b3-dmso-10-065]--[@b8-dmso-10-065] These processes result in a cluster of risk factors referred to as the metabolic syndrome (MetS).[@b9-dmso-10-065] MetS is comprised of abnormalities in central obesity, blood pressure, triglycerides, high-density lipoprotein (HDL) cholesterol, and fasting glucose, though the links between these processes continue to be elucidated.[@b10-dmso-10-065] MetS is highly heritable, underscoring both lifestyle and genetic underpinnings.[@b11-dmso-10-065] This underscores the potential for identification of individuals at risk for T2DM and CVD and also the opportunity to interrupt these processes with lifestyle modification and other treatments.[@b12-dmso-10-065]

In this review, we will consider the use of MetS as a concept clinically, first in considering traditional MetS criteria and then focusing on more recent linear scoring systems to assess CVD and T2DM risk in patient populations.

Diagnosis and epidemiology of metabolic syndrome using traditional criteria
===========================================================================

Traditional MetS criteria
-------------------------

MetS has traditionally been followed as a binary classification (which is to say, you have it or you do not) based on sets of criteria such as those by the National Cholesterol Education Program Adult Treatment Program III (ATP-III)[@b10-dmso-10-065] and the International Diabetes Federation,[@b13-dmso-10-065],[@b14-dmso-10-065] which each require an individual to have abnormalities in at least three of the components but have slightly different cutoff levels to designate abnormalities. The World Health Organization has a set of criteria that additionally requires evidence of insulin resistance, which requires additional laboratory testing such as an oral glucose tolerance test.[@b15-dmso-10-065] These sets of traditional MetS criteria have had demonstrated utility in their association with long-term risk of future T2DM[@b16-dmso-10-065],[@b17-dmso-10-065] and CVD,[@b18-dmso-10-065],[@b19-dmso-10-065] with odds ratios for future disease of 5.2 and 1.6, respectively, even if most studies have reported that this predictive ability does not typically appear to go beyond that of the individual components alone.[@b20-dmso-10-065],[@b21-dmso-10-065]

Epidemiology of MetS
--------------------

### Geography

Given its relationship to obesity, CVD, and T2DM, it is not surprising that the prevalence of MetS varies by geographical region worldwide. However, although there was previously a higher prevalence of MetS in more developed compared to less developed parts of the world, there has been a gradual shift toward high rates in many areas. The overall adult prevalence of 34.7% in the USA[@b22-dmso-10-065] now compares to 33.5% in urban India,[@b23-dmso-10-065] 27.5% in Malaysia,[@b24-dmso-10-065] 29.6% in Brazil,[@b25-dmso-10-065] and 7.3% in People's Republic of China.[@b26-dmso-10-065]

### Age and sex

The prevalence of MetS increases across the life span,[@b27-dmso-10-065] with a prevalence of ATP-III MetS of 9.8% in US adolescents aged 12--19 years,[@b28-dmso-10-065] 19% in adults 20--39 years, 34% in adults 40--59 years, and 47% in adults ≥60 years.[@b22-dmso-10-065] There are sex differences in MetS prevalence that vary across the age range, with a male vs female predominance in adolescence (10.9% vs 6.29%) that reverses by mid-adulthood (18% vs 20% at age 20--39 years) and widens thereafter in later adulthood (42% vs 51% by age ≤60 years).[@b22-dmso-10-065] In particular, women have a higher prevalence of ATP-III MetS after menopause.[@b29-dmso-10-065] Interestingly, there is some evidence that CVD risk associated with MetS may differ based on sex, with MetS appearing to confer greater risk among females compared to males.[@b20-dmso-10-065]

### Race/ethnicity

The racial/ethnic variation in MetS using traditional criteria bears detailed consideration.[@b27-dmso-10-065] In the USA, the prevalence of MetS is higher among non-Hispanic Whites (34.1%) and Hispanics (34.3%) compared to non-Hispanic Blacks (30.4%).[@b22-dmso-10-065] This tendency toward lower prevalence of MetS is particularly pronounced among African American men.[@b27-dmso-10-065] The low prevalence of traditional MetS among non-Hispanic Blacks is surprising given a higher degree of insulin resistance[@b30-dmso-10-065],[@b31-dmso-10-065] and high rates of T2DM[@b32-dmso-10-065] and death from CVD[@b2-dmso-10-065] in this group. This raises concern that MetS may miss risk detection in this group.[@b33-dmso-10-065],[@b34-dmso-10-065]

Current MetS criteria may not take into account racial/ethnic differences in the way MetS is manifested between racial ethnic groups.[@b12-dmso-10-065] The International Diabetes Federation and harmonized criteria do allow for different cutoffs of waist circumference by different racial ethnic groups, acknowledging the potential for different thresholds of risk, particularly among Asian and potentially Hispanic individuals.[@b35-dmso-10-065] But none of the criteria take into account that non-Hispanic Black individuals have lower triglycerides (TG) levels at baseline and are thus less likely to exhibit TG levels above population-based cutoffs,[@b33-dmso-10-065],[@b34-dmso-10-065] though as a group non-Hispanic Blacks still have gradual rise in TG with worsening insulin resistance.[@b36-dmso-10-065] We also found a lower prevalence of low HDL levels among African American adolescent males compared to Whites, a tendency that persisted through adult age ranges.[@b27-dmso-10-065] This lower prevalence of low HDL was not seen among African American adolescent or adult females, suggesting further sex differences in the classification of MetS.

It may not be surprising, then, that among African Americans, ATP-III MetS has a poorer association with other MetS-related risk factors, including insulin,[@b37-dmso-10-065] C-reactive protein (CRP),[@b38-dmso-10-065] and uric acid.[@b39-dmso-10-065],[@b40-dmso-10-065] Therefore, if used as a risk predictor, ATP-III MetS may not identify some African American individuals who otherwise appear to have abnormalities associated with CVD risk.

Limitations of traditional MetS criteria
----------------------------------------

Traditional MetS criteria are further limited by identifying risk only when a person exhibits abnormalities beyond the cutoffs for three of the components. This denies that MetS likely exists as a spectrum of risk, as seen in the increase in risk for individuals who have increasing numbers of abnormalities in the underlying MetS components.[@b20-dmso-10-065],[@b41-dmso-10-065] Because of this, it is likely that an individual with measurements in the MetS components just below the threshold for all five components may be at higher risk than someone who just exceeds the cutoffs in three components but has low or normal levels of the other two.

Use of traditional MetS criteria also leads to an inability to follow individuals over time for changes in their MetS status over time (with the exception of being positive or negative for MetS), which has likely contributed to noted instability of the diagnosis over time.[@b42-dmso-10-065],[@b43-dmso-10-065]

Continuous MetS scores
======================

Over the past several years, continuous measures of MetS have continued to emerge, both as a way to address some of the limitations of traditional MetS criteria and as a means of providing improved statistical power in research studies.[@b44-dmso-10-065] Techniques for generating these scoring systems have been reviewed elsewhere.[@b44-dmso-10-065] In general, these scoring systems utilize the MetS components from the ATP-III criteria, with some variation regarding the estimate of adiposity, particularly in pediatric scores. The majority of scores have utilized standardized *Z*-scores for each of the components, generated from the population being studied. In this approach, these *Z*-scores are then summed to create an overall estimate of MetS.[@b45-dmso-10-065]--[@b53-dmso-10-065] Other scores have used principal component analysis,[@b47-dmso-10-065],[@b54-dmso-10-065]--[@b56-dmso-10-065] whereas some scores instead use summed centile rankings[@b57-dmso-10-065],[@b58-dmso-10-065] or confirmatory factor analysis.[@b59-dmso-10-065] Overall, these scores have been generated more commonly in pediatric cohorts compared to adult cohorts, potentially owing to a set of pediatric MetS criteria that is both officially recognized and widely used.

We formulated a set of continuous MetS severity scores that are based on data that are nationally representative for the US population.[@b60-dmso-10-065],[@b61-dmso-10-065] To do so, we utilized confirmatory factor analysis on data from the National Health and Nutrition Examination Survey to assess how the five classic MetS components contribute differentially to the latent MetS factor. This acknowledges that the individual MetS components may contribute differentially to an estimate of the overall severity of MetS.

Because of the differences in correlation between MetS and other CVD risk factors by race/ethnicity[@b37-dmso-10-065]--[@b40-dmso-10-065] and because of the differences in MetS-related risk by sex,[@b20-dmso-10-065] we performed the confirmatory factor analysis on a sex- and race/ethnicity-specific basis and found differences in the factor loadings of the five MetS components between sex and racial/ethnic groups. We thus formulated equations on a sex- and race/ethnicity-specific basis. We also performed these analyses for both adolescents (aged 12--19 years) and adults (aged 20--64 years). Thus, this yielded a total of 12 age-, sex-, and race/ethnicity-specific basis ([Table 1](#t1-dmso-10-065){ref-type="table"}) used by multiplying a given patient's clinically measured values by subgroup-specific coefficients -- which has fortunately been made more manageable via an online calculator (<http://mets.health-outcomes-policy.ufl.edu/calculator/>).

It should be noted that this approach formulated the score solely based on how the individual MetS components cluster together and not directed at outcomes prediction. This is unlike the Framingham Risk Equation,[@b62-dmso-10-065] the American Heart Association score,[@b63-dmso-10-065] the FINRISK score[@b64-dmso-10-065] (all for cardiovascular risk), or the AUSDRISK score,[@b65-dmso-10-065] or the American Diabetes Association risk score[@b66-dmso-10-065] (both for T2DM risk), which were all formulated based on baseline characteristics using outcomes data to drive the score's calculation. As we will see, the MetS severity score, despite its roots purely as a MetS severity assessment, does correlate nonetheless with long-term cardiovascular and diabetes outcomes. The unique approach in its formulation may provide additional information regarding the pathophysiological processes behind MetS that is not captured in the outcomes-based score formulation.

Benefits of continuous MetS scores over traditional criteria
------------------------------------------------------------

As alluded to previously, continuous MetS scores acknowledge that there is a continuum of risk related to the processes underlying abnormalities in the components of MetS. From a clinical perspective, MetS scoring systems such as these (unlike binary MetS criteria) can be used to follow for the degree of change over time in a population,[@b52-dmso-10-065],[@b67-dmso-10-065] including assessing potential influences of MetS severity over time,[@b68-dmso-10-065] comparing differences between sex and racial groups,[@b67-dmso-10-065] and evaluating for differences in the rate of change by clinical status, such as change over the menopausal transition.[@b69-dmso-10-065] For example, our recent evaluation for changes in MetS severity during the menopausal transition revealed that Black women in particular have a more rapid rise in MetS severity in the few years leading up to menopause and the perimenopausal period before having a subsequently slower rate of rise after menopause. The overall goal of that and other similar analyses is to determine specific groups or periods of time when changes in MetS-related risk may be highest. These groups or time periods could then be more intensely targeted for lifestyle modification treatment.

Clinical assessment of continuous MetS scores
=============================================

Associations with other cardiovascular risk factors
---------------------------------------------------

The true utility of continuous MetS scores rests in their ability to estimate risk. The first validation of linear scores of MetS is with other measures associated with cardiovascular risk. Multiple studies demonstrated that continuous MetS scores correlated positively with adverse lifestyle factors[@b46-dmso-10-065],[@b50-dmso-10-065],[@b56-dmso-10-065],[@b70-dmso-10-065] or response to exercise training.[@b51-dmso-10-065] Other studies have used cross-sectional evaluation of continuous scores for linear relationships with other CVD risk factors, such as inflammatory factors and adiponectin.[@b53-dmso-10-065] Similarly, we found that our score was associated with surrogates of future disease,[@b8-dmso-10-065] including current levels of fasting insulin, CRP, and uric acid in both adults and children ([Figure 1](#f1-dmso-10-065){ref-type="fig"}); associations were true for each of the three racial/ethnic groups for which the score was formulated.[@b60-dmso-10-065],[@b61-dmso-10-065] We also evaluated longitudinally collected data to demonstrate long-term associations between childhood MetS scores and adult levels of insulin and adiponectin.[@b71-dmso-10-065] Finally, Magnussen et al[@b72-dmso-10-065] used a longitudinal approach of a cohort in Finland with a mean age of 13 years at baseline and 37 years at follow-up. They demonstrated that MetS as assessed in childhood using five different continuous MetS scores (including our score) was significantly linked to carotid intima media thickness during adulthood.[@b72-dmso-10-065] All these support external validity of continuous MetS scores for estimating the presence of the underlying processes associated with disease risk.

Associations with future disease
--------------------------------

The more important validation of linear scores of MetS is with long-term outcomes, including CVD and T2DM. This type of data is clearly more difficult to obtain, as it requires several years of follow-up; nevertheless, validations using this approach continue to emerge. Magnussen et al[@b72-dmso-10-065] evaluated their 24-year follow-up data from adolescence through adulthood, demonstrating that four of the five continuous MetS scores evaluated were associated with future risk for T2DM. For example, one of the scores tested was our MetS severity score, with a relative risk of future T2DM of 1.78 for every standard deviation (SD) increase in MetS severity.[@b72-dmso-10-065] Povel et al[@b59-dmso-10-065] evaluated a large Dutch cohort of adults (mean age 49 years) for future T2DM and CVD, reporting that each SD of continuous MetS score carried a hazard ratio of 3.58 for future T2DM and 1.31 for future CVD.

We evaluated long-term outcomes data for our score in a cohort from the Princeton region in Cincinnati, for whom MetS components were assessed as children (mean age 13 years) and adult outcomes were assessed at two time points, at mean ages of 38 and 50 years.[@b73-dmso-10-065],[@b74-dmso-10-065] We found that individuals who had developed CVD and/or T2DM by age 38 had significantly higher MetS severity scores in childhood. Each increase in 1 SD in score at childhood increased the odds of disease by age 38 years by 9.8 for future CVD and 2.7 for future T2DM. Each SD increase in score for MetS severity as adults (at mean age 38 years) increased the odds for later disease by 2.4 for CVD and 2.8 for T2DM.[@b73-dmso-10-065],[@b74-dmso-10-065] This slightly higher odds ratio for future T2DM is similar to the analysis of Povel et al,[@b59-dmso-10-065] who evaluated baseline MetS among adults and found a higher hazard ratio for future T2DM (2.7) than for CVD (1.25). Interestingly, the change in MetS severity score between childhood and adulthood carried further increases in risk for future disease, emphasizing the potential utility to follow the score over time ([Figure 2](#f2-dmso-10-065){ref-type="fig"}).[@b73-dmso-10-065],[@b74-dmso-10-065] Also, MetS severity remained significantly associated with these outcomes, including after the addition of other risk factors such as fasting insulin and adiponectin to these models,[@b71-dmso-10-065] suggesting that the score may capture additional estimates of risk beyond some current markers for the pathway of insulin sensitivity. Finally, the area under the curve (AUC) for disease prediction by age 38 and 50 years was 0.91 and 0.65 for CVD and 0.69 and 0.68 for T2DM -- suggesting a reasonable degree of discrimination between those at risk.[@b73-dmso-10-065],[@b74-dmso-10-065]

The value of these correlations between MetS severity and future disease depends partly on the emphasis on sensitivity vs specificity. After reporting these correlations, Magnussen et al[@b72-dmso-10-065] concluded from their data that continuous MetS scores did not adequately discriminate between individuals at risk for adult outcomes. Our data suggested a higher degree of discrimination (AUC: 0.68 for T2DM) compared to theirs (AUC: 0.62),[@b75-dmso-10-065] though we were still unable to determine an obvious cutoff to mark particular increases in risk. Future research will be needed to provide clinically useful thresholds for determination of particularly elevated risk. In addition, combining MetS severity with other risk determinants (such as low-density lipoprotein cholesterol or smoking) or other risk scores (such as the Framingham Risk Equation, the American Heart Association score,[@b63-dmso-10-065] or the American Diabetes Association risk score[@b66-dmso-10-065]) may improve accuracy of risk prediction.

Implications for practitioners
==============================

Use of continuous MetS scores provides a potential opportunity for clinicians in 1) determining baseline risk of future disease of their patients and 2) following changes in this disease risk over time. Following confirmative research to demonstrate efficacy, and potential evidence-based guideline recommendations, individuals with particularly high MetS severity could ultimately be started on therapy such as metformin to reduce hepatic glucose production[@b76-dmso-10-065] or statins to reduce overall CVD risk, as can be done for elevated CRP levels.[@b4-dmso-10-065],[@b77-dmso-10-065] The MetS severity score could then be used for tracking response to treatment. Given the importance of lifestyle modification for improvement of MetS-related disease risk,[@b78-dmso-10-065] elevated levels may also be used to motivate patients toward physical activity or dietary changes.[@b12-dmso-10-065] Although it is true that all individuals would benefit from making these lifestyle changes, such changes clearly carry a greater short-term risk reduction among some patients more than others. The potential for motivation is illustrated well by the National Weight Control Registry, a cohort of individuals who lost at least 13.6 kg of weight and kept it off for at least 1 year. Among registry members, 83% reported a specific trigger leading to their lifestyle changes and 23% listed this as a medical reason, including their physician's recommendation.[@b79-dmso-10-065] An elevated MetS severity score could be one of those triggers that strikes provide patients in a predisease state and offers them an opportunity to make changes to avoiding later disease. These scores patients with a single number on which to focus (integrated from multiple risk factors) that may be more easily followed than following variable changes in multiple risk factors at once.

However, as alluded to previously, clinical use of these scores will benefit from defined cutoffs that indicate particularly high-risk patients. The irony of this is that continuous MetS scores were formed alongside traditional MetS criteria in part because of the artificial nature of cutoffs in the individual MetS components and a dichotomous risk categorization. Nevertheless, it is likely that in practice, the MetS scores themselves would be more easily used as risk indicators and patient motivators if they had set cutoffs themselves. This is because such cutoffs could be used to add specificity in counseling individual patients regarding their MetS-related risks. For example, with improved cut-off data, a physician could inform her patient "in long-term studies, individuals with a MetS score such as yours had a 40% chance of having a heart attack within 10 years". This degree of specificity could thus be used to motivate the patient toward change, and the score could be used to track response to intervention and alterations in risk thereafter.

Another potential limitation to current use of MetS scores is the complexity of calculating the scores. In the case of our score, this is feasible via online calculator (<http://mets.healthoutcomes-policy.ufl.edu/calculator/>) or potentially through specially prepared spreadsheet programs for score calculations. However, because of the need to enter each component measure individually, calculation of a given patient's MetS score by the physician during a clinical encounter may require an excessive amount of time. Thus, use of a MetS-based scoring system in a clinical environment is likely to be best facilitated by support staff (calculating the score using either a website or spreadsheet). Future use will be greatly assisted by automatic calculators in electronic medical records (EMRs). Such EMR calculators will require indicators of fasting status (needed for TG and glucose measures), but will otherwise provide added functionality of pop-up alerts identifying high-risk patients and patients who have exhibited a recent increase in score, triggering an escalation in intervention. One current drawback is that the majority of MetS severity scores require waist circumference measurements (not frequently assessed in clinical encounters); in the case of our score, this limitation will be overcome by a version of the score using body mass index, currently in development.

Thus, in the balance, these scores will experience an increase in clinical use after ongoing research into high-risk thresholds, EMR calculators, and body mass index-based scores -- all of which are likely to enhance utility and further these scores for risk identification and patient motivation.

Conclusion
==========

The clear links between MetS and future disease have raised the need for effective tools to identify individuals at highest risk. Continuous MetS scores hold promise as a way to integrate the abnormalities in multiple factors and provide an estimate of the severity of the processes driving these abnormalities. With continued research in this area, these scores may open the door toward evaluating CVD and T2DM risk, motivating patients, and tracking treatment progress over time -- advances that are much needed for turning the tide on worsening T2DM and CVD worldwide.
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![Correlations between MetS severity score and risk factors associated with the pathophysiology of MetS.\
**Notes:** MetS severity scores and concurrent measures of (**A**) homeostasis model of insulin resistance (HOMA), (**B**) high-sensitivity C-reactive protein, and (**C**) uric acid (all assessed among participants aged 20--64 years of the National Health and Nutrition Survey 1999--2008), and (**D**) adiponectin (assessed among members of the Princeton Lipid Research cohort). *R*^2^ values varied by race, with HOMA 0.44 for Whites and 0.36 for Blacks and Hispanics; ln(hsCRP) 0.17 for Whites and Blacks and 0.09 for Hispanics; uric acid 0.16 for Whites, 0.06 for Blacks and 0.03 for Hispanics; and adiponectin 0.22 for Whites and Blacks combined. Reprinted from *Metabolism*. 63(2). Gurka MJ, Lilly CL, Norman OM, DeBoer MD. An examination of sex and racial/ethnic differences in the metabolic syndrome among adults: a confirmatory factor analysis and a resulting continuous severity score. 218--225; Copyright 2014, with permission from Elsevier,[@b61-dmso-10-065] and DeBoer MD, Gurka MJ, Morrison JA, Woo JG. Inter-relationships between the severity of metabolic syndrome, insulin and adiponectin and their relationship to future type 2 diabetes and cardiovascular disease. *Int J Obes (Lond)*. Epub 2016 May 24,[@b71-dmso-10-065] with permission.\
**Abbreviations:** hsCRP, high-sensitivity C-reactive protein; MetS, metabolic syndrome; HOMA, homeostatic model assessment.](dmso-10-065Fig1){#f1-dmso-10-065}

![Odds ratios of future T2DM and CVD for every 1-point increase in MetS severity score.\
**Notes:** Among members of the Princeton Lipid Research Clinic cohort, MetS severity scores were measured at childhood (mean age 13 years) and mid-adulthood (mean age 38 years), and adult outcomes were determined in mid-adulthood and later adulthood (mean age 50 years). Data shown are odds ratios of future disease for every 1-point (ie, 1 standard deviation score) increase in MetS severity at baseline time point and for the change in MetS severity (Δ MetS) between childhood and mid-adulthood. Data from DeBoer et al.[@b73-dmso-10-065],[@b74-dmso-10-065]\
**Abbreviations:** MetS, metabolic syndrome; CVD, cardiovascular disease; T2DM, type 2 diabetes mellitus.](dmso-10-065Fig2){#f2-dmso-10-065}

###### 

Equations for sex- and race/ethnicity-specific metabolic syndrome severity *Z*-score

  ----------------------------------------------------------------------------------------------------------------------------
  **Adults aged 20--64 years**
  Males
   Non-Hispanic White = −5.4473+0.0125 × waist circumference − 0.0251 × HDL + 0.0047 × SBP + 0.8244 × ln(Tri) + 0.0106 × Glu
   Non-Hispanic Black = −6.3780+0.0232 × waist circumference − 0.0175 × HDL + 0.0040 × SBP + 0.5400 × ln(Tri) + 0.0203 × Glu
   Hispanic = −5.5459+0.0135 × waist circumference − 0.0278 × HDL + 0.0054 × SBP + 0.8340 × ln(Tri) + 0.0105 × Glu
  Females
   Non-Hispanic White = −7.2536+0.0254 × waist circumference − 0.0120 × HDL + 0.0075 × SBP + 0.5800 × ln(Tri) + 0.0203 × Glu
   Non-Hispanic Black = −7.1895+0.0304 × waist circumference − 0.0095 × HDL + 0.0054 × SBP + 0.4455 × ln(Tri) + 0.0225 × Glu
   Hispanic = −7.7516+0.0162 × waist circumference − 0.0157 × HDL + 0.0084 × SBP + 0.8872 × ln(Tri) + 0.0206 × Glu
  **Adolescents age 12--19 years**
  Males
   Non-Hispanic White = −4.9310+0.2804 × BMI *z*-score − 0.0257 × HDL + 0.0189 × SBP + 0.6240 × ln(Tri) + 0.0140 × Glu
   Non-Hispanic Black = −4.7544+0.2401 × BMI *z*-score − 0.0284 × HDL + 0.0134 × SBP + 0.6773 × ln(Tri) + 0.0179 × Glu
   Hispanic = −3.2971+0.2930 × BMI Z-score − 0.0315 × HDL + 0.0109 × SBP + 0.6137 × ln(Tri) + 0.0095 × Glu
  Females
   Non-Hispanic White = −4.3757+0.4849 × BMI *z*-score − 0.0176 × HDL+0.0257 × SBP+0.3172 × ln(Tri) + 0.0083 × Glu
   Non-Hispanic Black = −3.7145+0.5136 × BMI *z*-score − 0.0190 × HDL+0.0131 × SBP+0.4442 × ln(Tri) + 0.0108 × Glu
   Hispanic = −4.7637+0.3520 × BMI *z*-score − 0.0263 × HDL + 0.0152 × SBP + 0.6910 × ln(Tri) + 0.0133 × Glu
  ----------------------------------------------------------------------------------------------------------------------------

**Notes:** For each given sex and racial/ethnic subgroups, MetS severity *Z*-scores are generated from inserting an individual's clinically measured values for waist circumference (in centimeters), HDL (in milligrams per deciliter), SBP (in millimeters of mercury), natural-log of fasting triglycerides (in milligrams per deciliter), and fasting glucose (in milligrams per deciliter).

**Abbreviations:** BMI, body mass index; MetS, metabolic syndrome HDL, high-density lipoprotein; SBP, systolic blood pressure; Glu, glucose.
